Mylan Laboratories Limited
Mylan Laboratories Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various global markets. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on areas such as oncology, infectious diseases, and cardiovascular health. The company is renowned for its commitment to quality and accessibility, offering a diverse portfolio of over 1,000 products, including injectables and biosimilars. Mylan's innovative approach and robust manufacturing capabilities have positioned it as a trusted provider in the healthcare sector. With a strong market presence and a dedication to improving patient outcomes, Mylan Laboratories continues to achieve significant milestones, reinforcing its reputation as a key contributor to global health solutions.
DitchCarbon Score
How does Mylan Laboratories Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan Laboratories Limited's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mylan Laboratories Limited's reported carbon emissions
In 2021, Mylan Laboratories Limited reported total carbon emissions of approximately 770,900,000 kg CO2e, comprising 355,000,000 kg CO2e from Scope 1 emissions and 415,800,000 kg CO2e from Scope 2 emissions. This data indicates a slight increase in emissions compared to 2020, when total emissions were about 785,300,000 kg CO2e, with Scope 1 at 352,400,000 kg CO2e and Scope 2 at 432,900,000 kg CO2e. Mylan Laboratories has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of reduction targets suggests a need for further development in their sustainability strategy. The company’s emissions data is not cascaded from a parent organization, indicating that these figures are independently reported. Overall, Mylan Laboratories Limited's current emissions profile highlights the importance of establishing clear climate commitments and reduction strategies to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 352,400,000 | 000,000,000 |
| Scope 2 | 432,900,000 | 000,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mylan Laboratories Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
